INTRODUCTION
============

Bisphosphonates (BPs) are synthetic analogues of pyrophosphate. Their action on osteoclasts leads to inhibition of bone resorption \[[@B1]\]. Therefore, BPs have been used in the treatment of various diseases including resistant hypercalcemia, metabolic bone diseases, and osteoporosis \[[@B2]\]. The inhibitory effect of pyrophosphate on the precipitation of calcium phosphate (CaP) was initially demonstrated by Fleisch et al. in 1968 \[[@B3]\]. Since then, other investigators have shown that BPs inhibit urine crystallization of calcium oxalate (CaOx) and CaP by forming soluble aggregates with calcium for which they have high affinity \[[@B4]\]. BPs have been shown to work on all three phases of crystallization: nucleation, growth, and aggregation of CaOx and CaP crystals \[[@B4]\]. They also act on calcium ion transport at the cell membranes \[[@B5]\] through GTP-binding protein. Therefore, it has been hypothesized that BPs may be useful in the prevention of kidney stones.

We previously validated a simple and inexpensive *in vitro* crystallization assay for measuring turbidity by spectrophotometry in synthetic urine \[[@B6]\]. Using this method we investigated the inhibitory effect of various BPs on the crystallization of calcium oxalate monohydrate (COM), CaP, and magnesium ammonium phosphate (MAP) in synthetic urine. We aimed to see 1) which BPs work best on a particular type of crystal and 2) what is the lowest concentration of BPs that can inhibit crystal formation.

MATERIALS AND METHODS
=====================

1. Reagents
-----------

All reagents and BPs were obtained from Sigma (St. Louis, MO, USA).

2. Synthetic urine preparation
------------------------------

Synthetic urine was made by using a modified version of the method previously described by Ebisuno et al. \[[@B7]\] and was formulated to contain components present in normal urine. The composition of synthetic urine consisted of (mg/mL) the following: CaCl~2~ · H~2~O (0.65), MgCl~2~ · H~2~O (0.65), NaCl (4.6), Na~2~SO~4~ (2.3), Na~3^−^~ citrate · 2H~2~O (0.65), Na~2^−^~ oxalate (0.02), KH~2~PO~4~ (2.8), KCl (1.6), NH~4~Cl (1.0), urea (25), and creatinine (1.1), with a pH of 5.7. The composition of the synthetic urine was modified depending on the desired type of crystal.

3. The effect of BPs on COM crystallization in synthetic urine
--------------------------------------------------------------

Spectrophotometric measurement of turbidity was used to assess the effect of BPs on COM crystallization in synthetic urine. For this purpose, we used synthetic urine with a high concentration of calcium and without sodium oxalate. Therefore, we added CaCl~2~ · H~2~O (1.47) to the synthetic urine to reach a final calcium concentration of 10 mmol/L. In 1.5-mL microcentrifuge tubes we mixed 1 mL of synthetic urine and 125 µL of various concentrations of BPs from 0.001 to 2.5 mg/mL of synthetic urine. The solution was incubated at 37℃ for 10 minutes. To induce crystallization, sodium oxalate was added to reach a final concentration of 10 mmol/L. The solution was mixed well and incubated at 37℃ for 10 minutes. The turbidity was measured by spectrophotometry at 660 nm immediately after vortexing.

4. The effect of BPs on CaP crystallization in synthetic urine
--------------------------------------------------------------

Synthetic urine without Na-oxalate from which MgCl~2~ was removed was used. In 1.5-mL microcentrifuge tubes we mixed 1 mL of synthetic urine and 125 µL of various concentrations (0.001 to 2.5 mg/mL) of BPs. The solution was mixed thoroughly and incubated at 37℃ for 10 minutes. Then 300 IU jack bean urease was added. The solution was mixed well again and incubated at 37℃ for 10 minutes. Turbidity was measured by spectrophotometry at 660 nm immediately after vortexing.

5. The effect of BPs on MAP crystallization in synthetic urine
--------------------------------------------------------------

Synthetic urine without Na-oxalate from which CaCl~2~ was removed was used. In 1.5-mL microcentrifuge tubes we mixed 1 mL of synthetic urine and 125 µL of various concentrations (0.001 to 2.5 mg/mL) of BPs. The solution was incubated at 37℃ for 10 minutes, and 300 IU jack bean urease was added. The solution was mixed well and incubated at 37℃ for 10 minutes. The turbidity was measured by spectrophotometry at 660 nm immediately after vortexing.

The percent inhibitory activity (IA) was calculated by using the formula: (*a*−*b*)/*a*×100, where *a* is baseline maximal turbidity and *b* is maximal turbidity with various concentrations of medication.

RESULTS
=======

The range of effective doses of the various BPs that resulted in inhibition of crystallization of COM, CaP, and MAP in synthetic urine (expressed as IA) is presented in [Table 1](#T1){ref-type="table"}. The lowest dose at which we noticed an inhibitory effect was 0.001 mg/mL for alendronate, risedronate, and ibandronate. At this dose, alendronate had a similar low inhibitory effect on both COM (IA, 8%) and CaP (IA, 10%). At the same dose of 0.001 mg/mL, risedronate showed the highest IA for CaP (37%) and also prevented the crystallization of COM (18%), but needed a higher dose (0.002 mg/mL) for inhibition of MAP (IA, 30%). Ibandronate at the lowest dose of 0.001 mg/mL reduced the formation of COM crystals (IA, 24%) and CaP crystals (IA, 17%), but required a five-fold dose for the inhibition of MAP crystallization (IA, 11%). The initial inhibitory effect of etidronate was noticed at 0.004 mg/mL, inducing a similar IA for both COM and MAP (36% and 42%, respectively).

The dose-dependent effect of the BPs on each type of crystal is shown in [Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, and [3](#F3){ref-type="fig"}. With regard to the action of the BPs on a specific type of crystal, ibandronate had the strongest IA on COM (24%), whereas risedronate induced a higher IA of 37% on CaP at the lowest dose of 0.001 mg/mL. To initiate the inhibition of MAP crystallization, risedronate required a two-fold higher concentration (0.002 mg/mL) to reach 30% IA, whereas etidronate required a four-fold higher concentration (0.004 mg/mL) to reach 42% IA.

DISCUSSION
==========

The incidence of urolithiasis is increasing \[[@B8]\] and the current treatment is unsatisfactory, leading to high morbidity and an increased risk of reoccurrence \[[@B9][@B10]\]. Increasing evidence suggests that stone disease has multi-systemic involvement \[[@B11][@B12]\] and that vascular theory plays a major role in stone formation \[[@B13]\]. Therefore, new treatment strategies are imperative, especially in patients with severe disease presenting with kidney stone, osteoporosis, and arterial calcifications. Since all these conditions are affected by BPs through their action on calcium transport in cell membranes and on osteoclasts, BPs seem worthy of investigation.

To our knowledge, we are the first to report a comparison of the inhibitory effect of various BPs on the crystallization of three different salts: COM, CaP, and MAP. Using spectrophotometric measurement of urinary turbidity, a method we established in our laboratory, we found that BPs are good inhibitors of crystallization in synthetic urine \[[@B6]\]. Overall, BPs showed the best inhibitory effect on CaP and COM crystallization at clinically acceptable low doses. Higher doses of BPs were needed to prevent MAP crystallization. The difference in the IA of BPs on these three types of crystals is likely due to their high affinity for calcium, although our experiment was not designed to study the exact pathway of action of the BPs. Of all the BPs that we tested, both risedronate and ibandronate showed the strongest IA at the same low dose. This is explained by their high potency compared with the other BPs that we investigated. Higher IA was seen with higher concentrations of BPs. However, this has poor clinical significance since these concentrations cannot be safely reached in human urine.

The effect of BPs on stone formation has been reported in cell cultures \[[@B14]\] and in animal models \[[@B15]\]. Senzaki et al. \[[@B14]\] showed that alendronate inhibits CaP microlith formation in cell cultures. BPs decrease urinary calcium excretion in animal models \[[@B15]\]. Kawamura et al. \[[@B16]\] showed that etidronate can suppress the formation of CaOx renal stones induced by synthetic vitamin D and ethylene glycol in rats. They speculated that etidronate may inhibit stone formation by affecting the nidus formation, aggregation, and crystal growth of CaOx \[[@B16]\]. The main advantage of our work compared with the research mentioned above is that rather than looking at a single drug and a single crystal we studied the inhibitory effect of various BPs on all three types of crystals. This allowed a comparison between various BPs and different crystals.

There are only a few reports in the literature describing the role of BPs in patients with kidney stone. Small case reports have shown that etidronate \[[@B17]\], alendronate \[[@B18][@B19]\], and pamidronate \[[@B20]\] prevent hypercalciuria and reduce the risk of forming calcium stones \[[@B21][@B22]\]. In addition, treatment with these two drugs leads to normalization of markers of bone resorption \[[@B20]\]. Due to their strong inhibitory effect on bone resorption, BPs are currently indicated in patients with low bone density (osteopenia or osteoporosis), hypercalcemia, hypercalciuria, and urolithiasis \[[@B2][@B18][@B20]\]. BPs have been shown to prevent kidney stone formation after prolonged bed rest in adult patients \[[@B23]\]. Their use in pediatrics is restricted to recurrent extremity fractures and reduced bone mass \[[@B24]\]. The drugs are well tolerated and have few adverse effects \[[@B24]\]. However, animal studies have reported teratogenic effects at very high doses of BPs not used in clinical practice \[[@B25]\].

The advantages of our study are 1) the well-controlled environment (synthetic urine), 2) the simplicity and practicability of the method, and 3) the ability to study any type of crystal. The major study limitation is the difficulty of converting the BP doses we tested to clinically applicable doses. However, considering the pharmacokinetics of the BPs and taking into account average urinary output, we can conclude that the lowest tested doses are at an acceptable clinical level. Another study limitation is the inability to study the adverse effects of BPs in order to balance dose efficiency and potential harm.

CONCLUSIONS
===========

BPs are good inhibitors of crystallization in synthetic urine, with risedronate and ibandronate being the most potent agents. At a low clinically acceptable dose, the highest inhibitory action was on CaP and COM crystals, whereas higher doses were requited to prevent MAP crystallization. Further investigation of the use of BPs in kidney stone prevention is warranted.
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###### Range of effective doses of various bisphosphonates that resulted in inhibition of crystallization of COM, CaP, and MAP in synthetic urine (expressed as IA)

![](icu-61-310-i001)

  Medication      Range of effective dose (mg/mL)   Type of crystal   Range of IA (%)
  --------------- --------------------------------- ----------------- -----------------
  Etidronate      0.004--0.3                        COM               36--65
  0.021--0.3      CaP                               29--68            
  0.004--0.3      MAP                               42--71            
  Alendronate     0.001--0.625                      COM               8--73
  0.001--0.039    CaP                               10--63            
  0.039--0.625    MAP                               39--94            
  Risedronate     0.001--2.5                        COM               18--67
  0.001--0.625    CaP                               37--97            
  0.002--2.5      MAP                               30--98            
  Ibandronate     0.0012--1.25                      COM               24--77
  0.0012--0.078   CaP                               17--69            
  0.005--1.25     MAP                               11--91            

COM, calcium oxalate monohydrate; CaP, calcium phosphate; MAP, magnesium ammonium phosphate; IA, inhibitory activity.
